



CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-21, 27, 28, 48-59, 66-68 (completely); 25-26, 31-47
61-65 (partially)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-21, 27, 28, 48-59, 66-68 (completely); 25-26, 31-47, 61-65 (partially)

Subject-matter relating to angiotensin-converting enzyme inhibitor protein 3, represented by SEQ ID Nos 1-4, 9-12, 27

2. claims: 22, 23, 29, 60 (completely); 25-26, 31-47, 61-65 (partially)

Subject-matter relating to angiotensin-converting enzyme inhibitor protein 5, represented by SEQ ID Nos 15, 16

3. claims: 24, 30; 25-26, 31-47 (partially)

Subject-matter related to a polypeptide of SEQ ID Nos 25, 26

4. claim: 69

Subject-matter related to the polynucleotide of SEQ ID NO 28



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 99/67382 A (COMPUGEN LTD; MINTZ, LIAT; SAVITSKY, KINNERET) 29 December 1999 (1999-12-29) * page 36, line 28 - page 39, line 7 * * page 35, line 6 *	1-21, 25-28, 31-59, 61-68	C12N15/09 C12N15/12 C07K14/47 C07K16/08 C12P21/08 C12Q1/02 C12Q1/68
D,X	WO 99/55869 A (ZYMOGENETICS, INC) 4 November 1999 (1999-11-04) * page 64, line 14 - page 67, line 17; figure 1 *	1-21, 25-28, 31-59, 61-68	C12N1/15 C12N1/19 C12N1/21 C12N5/10
P,X	KOISHI RYUTA ET AL: "Angpt13 regulates lipid metabolism in mice" NATURE GENETICS, vol. 30, no. 2, February 2002 (2002-02), pages 151-157, XP002321851 ISSN: 1061-4036 * the whole document *	1-21, 25-28, 31-59, 61-68	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12N
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 21 March 2005	Examiner Lanzrein, M
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

1
EPO FORM 1503 03.82 (P04C04)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 73 3390

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-03-2005

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9967382 A	29-12-1999	AU 4643699 A WO 9967382 A2	10-01-2000 29-12-1999

WO 9955869 A	04-11-1999	AU 3661199 A WO 9955869 A1	16-11-1999 04-11-1999

专利名称(译)	测试用于治疗或预防诸如高脂血症的疾病的药物的方法		
公开(公告)号	EP1403367A4	公开(公告)日	2005-08-17
申请号	EP2002733390	申请日	2002-06-07
[标]申请(专利权)人(译)	株式会社三共		
申请(专利权)人(译)	SANKYO COMPANY LIMITED		
当前申请(专利权)人(译)	SANKYO COMPANY LIMITED		
发明人	KOISHI, RYUTA, C/O SANKYO COMPANY, LIMETED ANDO, YOSUKE, C/O SANKYO COMPANY, LIMITED ONO, MITSURU, C/O SANKYO COMPANY, LIMITED YASUMO, HIROAKI, C/O SANKYO COMPANY, LIMITED SHIMIZUGAWA, TETSUYA, C/O SANKYO COMPANY, LIMITED YOSHIDA, KENICHI, C/O SANKYO COMPANY, LIMITED SHIMAMURA, MITSURU, C/O SANKYO COMPANY, LIMITED FURUKAWA, HIDEHIKO, C/O SANKYO COMPANY, LIMITED		
IPC分类号	C07K14/47 C12N1/15 C12N1/19 C12N1/21 C12N15/12 C12P21/08 C12Q1/68 C12N15/09 C07K16/08 C12Q1/02 C12N5/10 C12P21/02 G01N33/15 G01N33/53		
CPC分类号	C07K14/47 C12Q1/6883 C12Q2600/136 C12Q2600/158		
优先权	2001357037 2001-11-22 JP 2001384103 2001-12-18 JP 2001300715 2001-09-28 JP 2001178548 2001-06-13 JP 2001300716 2001-09-28 JP 2002103583 2002-04-05 JP 2001173758 2001-06-08 JP 2001213334 2001-07-13 JP		
其他公开文献	EP1403367A1		
外部链接	Espacenet		

摘要(译)

本发明旨在提供一种测试选自高脂血症，动脉硬化和高血糖症的至少一种疾病的治疗方法或预防方法的新方法。更具体地，一种方法，包括在存在或不存在测试物质的情况下培养培养的细胞，检测“血管生成素相关蛋白3或4”基因的mRNA表达剂量，启动子活性或蛋白质产生水平，从而选择测试物质与在不存在下培养的细胞相比，在其存在下培养的细胞中检测到的mRNA表达剂量，启动子活性或蛋白质产生水平降低。

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim:	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
Category	Citation of document with indication, where appropriate, of relevant passages.		
X	WO 99/67382 A (CORPUGEN LTD; MINTZ, LIAT; SAVITSKY, KINBERET) 29 December 1999 (1999-12-29) - page 36, line 28 - page 39, line 7 - - page 35, line 6 -	1-21, 25-28, 31-59, 61-68	C12N15/09 C12N15/12 C07K14/47 C07K16/08 C12Q1/68 C12Q1/02
D,X	WO 99/55869 A (ZYMOGENETICS, INC) 4 November 1999 (1999-11-04) - page 64, line 14 - page 67, line 17; figure 1 -	1-21, 25-28, 31-59, 61-68	C12N1/15 C12N1/19 C12N1/21 C12N5/10
P,X	KOISHI, RYUTA ET AL: "Angptl3 regulates lipid metabolism in mice" NATURE GENETICS, vol. 30, no. 2, February 2002 (2002-02), pages 151-157, XP00221851 ISSN: 1061-4036 - the whole document -	1-21, 25-28, 31-59, 61-68	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 7) C12N
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Munich		21 March 2005	Examiner Lanzrein, M
CATEGORY OF CITED DOCUMENTS X: prior art patent document, not published in, or Y: prior art patent document, published in, or Z: non-patent literature document D: document cited for other reasons P: document of the same patent family, corresponding document			